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Edited by Hans-Dieter KlenkAbstract Using a high throughput screen based on the inter-
action of the HIV-1 gp41 ectodomain with the virucidal protein
cyanovirin-N (CV-N), we isolated two new peptides which
inhibited the binding of CV-N to gp41 and which subsequently
showed anti-HIV activity in a whole cell assay. A 5-kDa
(contrajervin) and 10 kDa (treculavirin) peptide were isolated
from Dorstenia contrajerva and Treculia obovoidea, respectively.
Treculavirin was composed of two subunits, each containing 50
amino acid residues, which are covalently linked by at least one
disulﬁde bond between the subunits. Both peptides were shown
to bind to gp41 and gp120 and to inhibit the cytopathic eﬀects
of HIV-1RF infection in a human T-lymphoblastoid cell line
(CEM-SS).
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Infection of cells by HIV-1 requires virus-cell fusion, a
process which is mediated in part by the viral envelope gly-
coprotein gp41. Compounds which inhibit this interaction by
binding to gp41 are capable of inhibiting viral entry into host
cells [1]. Cyanovirin-N (CV-N) is an anti-HIV protein origi-
nally isolated from the cyanobacterium Nostoc ellipsosporum
[2], whose activity is due to high-aﬃnity binding to gp120 and
gp41 envelope glycoproteins [3]. Based on this interaction, an
assay was developed to ﬁnd compounds that could bind
competitively to gp41 in a manner similar to CV-N, therefore
providing new antiviral leads [4]. The assay involves compe-
tition for CV-N binding to passively immobilized gp41, using
time-resolved ﬂuorescence detection of europium-labeled CV-
N. Extracts that showed activity in the initial screen were
further prioritized by eliminating those whose gp41 binding* Corresponding author. Fax: +1-301-846-6177.
E-mail address: manuscripts@ncifcrf.gov (T.C. McKee).
Abbreviations: CV-N, cyanovirin-N; LC–MS, liquid chromatography–
mass spectrometry; HPLC, high-performance liquid chromatography;
TFA, triﬂuoroacetic acid; HTS, high throughput screening; UDA,
Urtica diocia agglutinin; PEC, S-(b-4-pyridylethyl)cysteine; ESI-MS,
electrospray ionization mass spectra; BSA, bovine serum albumin;
PBS, phosphate buﬀered saline; glcNAc, N -acetylglucosamine
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doi:10.1016/j.febslet.2004.04.085could be blocked by the sugars mannose and N -acetylglucos-
amine (glcNAc), indicating monosaccharide-speciﬁc lectin ac-
tivity. Two plant extracts that met the criteria were selected for
bioassay-guided fractionation and subsequently yielded 5- and
10-kDa peptides.
Dorstenia contrajerva and Treculia obovoidea are plants in
the Moraceae family, which are found in tropical and sub-
tropical areas. Various plant parts of D. contrajerva have been
used in traditional medicines to reduce fever and to treat colds,
diarrhea, and snakebites, and the reported activity was at-
tributed to coumarins, chalcones, ﬂavones and ﬂavanones [5].
The genus Treculia contains three species, the best known
being Treculia africana (African breadfruit). Reported com-
ponents of this staple food include polyphenols and polysac-
charides as well as a high content of fatty acids and essential
amino acids. There is no reported literature on T. obovoidea.
To the best of our knowledge, this is the ﬁrst report of peptides
or anti-HIV activity from either genus.
This paper describes two peptides isolated from the leaves of
D. contrajerva and the bark of T. obovoidea. The Dorstenia
peptide, contrajervin, is a 5-kDa, 46 amino acid monomer
containing eight disulﬁde bridge-linked cysteine residues. The
Treculia peptide, treculavirin, is a 10-kDa, 100 amino acid
dimer containing 20 cysteine residues, all of which are involved
in disulﬁde bonds, and at least one of these disulﬁde bonds is
between the two 50 amino acid monomers. The two peptides
show high primary sequence similarity to each other as well as
to chitinase and hevein-like proteins.2. Materials and methods
2.1. General experimental procedures
All solvents were high-performance liquid chromatography (HPLC)
grade and were purchased from EM Science. Endoproteinases were
obtained from Roche Molecular Biochemicals (Indianapolis, IN). The
gp41 (recombinant, glycosylated, HIV-1HxB2 gp41 and ecto domain)
was purchased from Viral Therapeutics, Inc. (Ithaca, NY) and the
gp120 (native, glycosylated and HIV-1IIIB gp120) from Advanced
Biotechnologies Inc. (Columbia, MD). The gp120 (recombinant, gly-
cosylated and HIV-1BaL gp120) was obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH. Electrospray ionization mass spectra (ESI-MS) were acquired on
a Hewlett–Packard HP1100 integrated liquid chromatography–mass
spectrometry (LC–MS) system. Amino acid sequences were deter-
mined by Edman degradation using an Applied Biosystems Model 494
sequencer. All HPLC mobile phases included 0.05% (v/v) triﬂuoro-
acetic acid (TFA).blished by Elsevier B.V. All rights reserved.
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Plant material was obtained under NCI contract and voucher
specimens are maintained at the Smithsonian Institute. Leaves of
D. contrajerva L. were collected at the Altun-Ha Ruins in Belize,
British Honduras in March 1990. The dried plant material (449 g) was
ground and sequentially extracted with methanol–methylene chloride
1:1 v/v, followed by 100% methanol. The plant material was then dried,
extracted with water, and lyophilized to yield 23.6 g of aqueous extract.
Stembark of T. obovoidea N. E. Br. was collected in Woleu Ntem
province, Gabon, Africa in February 1992. The dried plant material
(446 g) was treated as described above to yield 8.4 g of aqueous extract.
2.3. Isolation and puriﬁcation of peptides
A 5.0-g portion of the aqueous extract of D. contrajerva was sub-
jected to vacuum-liquid chromatography on Bakerbond wide pore C4
media (8 5 cm), eluting with a total of 2 L of a stepwise gradient of 0–
100% methanol. The bioactive water–methanol 2:1 v/v fraction was
lyophilized to yield 430 mg of powder which was precipitated with 50
ml of water–ethanol 1:1 v/v at )20 C overnight. The resulting pre-
cipitate (190 mg) was resuspended in 15 ml of water and ﬁltered
through an Amicon Centriprep 3000 molecular weight cutoﬀ ﬁlter. The
>3000 Da retentate (93 mg) was puriﬁed using reversed-phase HPLC
(Dynamax C4, 1 25 cm, 300 A) eluting with a linear gradient of 0–
60% acetonitrile in water over 40 min at a ﬂow rate of 3 ml/min to yield
7.5 mg of contrajervin.
A 2.0-g portion of the aqueous extract of T. obovoidea was subjected
to vacuum-liquid chromatography as above. The bioactive water–
methanol 2:1 v/v fraction was lyophilized to yield 417 mg of powder. A
100-mg portion of this was chromatographed on Sephadex LH-20
(95 2.5 cm), eluting with water–methanol 3:1 v/v. An early eluting
fraction (13.3 mg) was further puriﬁed by reversed-phase HPLC
(Hamilton PRP-3, 1 25 cm, 300 A) eluting with a gradient of 5–30%
acetonitrile in water over 45 min at a ﬂow rate of 3 ml/min to yield 0.6
mg of treculavirin.
2.4. Sequence determination
For contrajervin, disulﬁde bonds were reduced and alkylated as
previously described [6]. The derivatized peptide was puriﬁed by re-
versed-phase HPLC (Dynamax C4, 300 A) using a gradient elution of
0.05% aqueous TFA for 40 min, then increasing to 50% acetonitrile in
water over 60 min. The S-(b-4-pyridylethyl)cysteine (PEC) derivative
(250 lg) was subjected to endoproteinase Asp-N and trypsin (both
from Boehringer–Mannheim GmbH) digestion as per the manufac-
turer’s instructions at an enzyme/substrate ratio of 1:40 and 1:10,
respectively. The cleaved peptide products were puriﬁed by reversed-
phase HPLC (Dynamax C4, 300 A) using a gradient of water for 20
min, then increasing to 50% acetonitrile over 90 min. The PEC de-
rivative and digested fractions were sequenced by Edman degradation
and analyzed by LC–MS to conﬁrm the complete sequence.
For treculavirin, disulﬁde bonds were reduced and alkylated as
previously described [7] with the following change. The reaction mix-
ture was maintained at 37 C for 17 h for reduction and 25 h for al-
kylation. The reduced and alkylated products were each analyzed by
ESI-MS. The PEC derivative was puriﬁed by reversed-phase HPLC
(Hamilton PRP-3, 300 A) using a gradient elution of water for 30 min,
then increasing to 50% acetonitrile in water over 30 min. The PEC
derivative (250 lg) was subjected to endoproteinase Asp-N and trypsin
digestion as per the manufacturer’s instructions at an enzyme/substrate
ratio of 1:50 and 1:20, respectively. The cleaved peptide products were
puriﬁed by reversed-phase HPLC (Hamilton PRP-3, 300 A) using a
gradient of water for 30 min, then increasing to 40% acetonitrile over
30 min and to 100% acetonitrile over an additional 10 min. The di-
gested fractions were sequenced by Edman degradation and analyzed
by LC–MS to conﬁrm the complete sequence.
2.5. Biological assays
Fractions and pure peptides were screened in a high throughput
screening (HTS) assay that measured inhibition of the binding of la-
beled CV-N to gp41 as previously described [4]. This is a solid-phase
competition-binding assay using time-resolved ﬂuorescence detection
of europium Euþ3-labeled CV-N. The recombinant gp41 utilized for
this assay was fully glycosylated and was in the form of a fusion-active
six-helix bundle representing the ectodomain of gp41 [8]. In brief,
samples in 1% bovine serum albumin (BSA) in phosphate buﬀeredsaline (PBS) were preincubated with plate-bound gp41 in a 96-well
plate format at room temperature. Euþ3-labeled CV-N was then added
and the plates were incubated again at room temperature before being
washed with PBS containing 0.05% Tween 20 (TBPS). DELFIA
enhancer solution (Perkin–Elmer Life Sciences) was added to solubilize
the bound europium and ﬂuorescence was measured in time-resolved
mode using a Perkin–Elmer Life Sciences Victor2TM ﬂuorometer.
An XTT-tetrazolium based assay was used to conﬁrm the anti-HIV
activity of the pure peptides. This assay, as previously described [9],
measures the viability of virus-infected CEM-SS cells by the metabolic
reduction of the tetrazolium salt, XTT, to a soluble, colored formazan
product which can be quantitated by spectrophotometry.
Further studies on biological activity were done with contrajervin
only, due to the limited mass of treculavirin. To determine whether
contrajervin also inhibited the binding of labeled CV-N to gp120,
ELISA plates were treated as in the gp41 assay with the following
modiﬁcations. 25 ng of gp120BaL and gp120IBaL was bound to separate
96-well plates, which were then rinsed with TBPS and blocked with
PBS containing BSA. The plate was rinsed with TPBS, then incubated
with eight serial dilutions of contrajervin starting at a high concen-
tration of 50 lg/ml for 30 min before adding 100 ng/well of Euþ3-la-
beled CV-N. The plate was again rinsed with TPBS before the addition
of the DELFIA enhancer solution.
To determine whether the peptide may be an inhibitor of HIV
binding and/or fusion, the eﬀect of delayed addition of contrajervin to
HIV-1RF infected cells was studied using a previously described
method [10]. An XTT assay was carried out with contrajervin added to
quadruplicate wells at 0, 2, 4, 6, 8, 12, and 24 h after addition of the
virus. After seven days of incubation, the cultures were observed mi-
croscopically for the presence of cytopathic eﬀects (syncytia) and then
stained with XTT.
Contrajervin was subjected to a chitin-binding assay as previously
described [11]. The peptide and a wheat germ agglutinin (WGA)
control were applied to chitin microcolumns and eluted sequentially
with PBS and 0.1 M acetic acid. Samples were desalted and analyzed
by reversed-phase HPLC (Dynamax C4, 300 A) using a gradient of
0–60% acetonitrile in water over 45 min at a ﬂow rate of 3 ml/min.3. Results and discussion
3.1. Peptide characterization and structure
The aqueous extract of D. contrajerva was subjected to re-
versed-phase vacuum-liquid chromatography, ethanol precip-
itation, size exclusion ﬁltration and reversed-phase HPLC to
yield 7.5 mg of contrajervin. ESI-MS analysis of the native
protein provided a molecular weight of 5103.8 Da, which is in
agreement with the theoretical calculated molecular weight of
5104.5. The native protein was reduced and alkylated, yielding
an ESI-MS weight of 5952.7 Da, which was consistent with the
presence of eight disulﬁde-linked cysteines. Direct sequencing
of the PEC derivative provided a primary sequence of 33
amino acids. The PEC derivative was subjected to endopro-
teinase Asp-N digestion to yield three fragments, two of which
provided overlapping conﬁrmation of the sequence, while the
third fragment extended the primary sequence to 43 amino
acids. Trypsin digestion of the PEC derivative also resulted in
three fragments, two providing overlapping conﬁrmations,
with the third fragment extending the sequence to a ﬁnal count
of 46 amino acids (Fig. 1(A)).
The aqueous extract of T. obovoidea was subjected to vac-
uum-liquid chromatography, size exclusion column chroma-
tography and reversed-phase HPLC to yield 0.6 mg of
treculavirin. ESI-MS analysis of pure treculavirin gave two
molecular ions of 10 369 and 10 427 Da, indicating that it ex-
hibited heterogeneity. Reduction of the native protein yielded
two fragments with molecular weights of 5194.6 and 5252.0,
suggesting the presence of two monomers covalently linked via
one or more disulﬁde bonds. ESI-MS of the reduced and
Fig. 2. Eﬀect of addition of simple sugars on the ability of D.
contrajerva and T. obovoidea to compete with CV-N binding to gp41.
A contrajervin
1  10      20         30              40
ERDDHRCGPDYGNPSCSGDRCCSIYNWCGGGSSYCSGGSCRYQCWY     
             PEC
             Asp-N 
Trypsin 
B treculavirin
1 10      20 (E)         30             40  50 
PGCEERPDHQCGPDYGNPGCGAGRCCSIHGWCGSSADYCSGTSCQYQCSC 
     Trypsin 
      Asp-N 
Fig. 1. (A) Primary amino acid sequence of native contrajervin ob-
tained after digestion with endoproteinases Asp-N and trypsin. Arrows
indicate sequenced peptide fragments. (B): Primary amino acid se-
quence of one of the monomers of treculavirin obtained after digestion
of the PEC derivative with endoproteinases, trypsin and Asp-N.
Parentheses above residue 22 indicates interchanging alanine and
glutamic acid residues.
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indicating that each monomer contained 10 cysteines.
One of the PEC monomers was subjected to trypsin diges-
tion which yielded two fragments. Edman degradation of the
ﬁrst fragment provided a sequence of 22 amino acids and de-
ﬁned the microheterogeneity, with the monomer existing with
interchanging alanine and glutamic acids at residue 22. The
second fragment provided a sequence of 23 amino acids. Di-
gestion of the second PEC monomer gave similar results. The
PEC monomers were then digested with endoproteinase Asp-
N to yield three fragments, all of which overlapped the trypsin
fragments and provided the ﬁnal monomer sequence of 50
amino acids (Fig. 1(B)). The calculated theoretical molecular
weights of the native protein, 10371.3 and 10429.3 Da, sup-
ported the deduced 100 amino acid primary sequence.
3.2. Biological activity
Contrajervin and treculavirin showed 50% displacement of
labeled CV-N from gp41 at a concentration of 0.59 and 0.20
lM, respectively. Contrajervin also showed 50% displacement
of CV-N from native gp120 obtained from a T-tropic virus
(gp120IIIB) and recombinant gp120 derived from an M-tropic
virus (gp120BaL) at a concentration of 0.20 lM. In a whole cell
assay, contrajervin inhibited the cytopathic eﬀects of HIV-1RF
infection in a human T-lymphoblastoid cell line (CEM-SS),
with an EC50 value of 1.0 lM and an IC50 value of >4.9 lM.
Treculavirin showed anti-HIV activity at an EC50 value of
<0.02 lM and an IC50 value of > 2.5 lM. For both com-
pounds, an in vitro ‘‘therapeutic index’’ was not obtained as no
toxicity was observed at the highest dose tested. Attempts to
identify an IC50 were not pursued due to the limited amounts
of material available.
A time course experiment was performed in which aliquots
of contrajervin were added at various times following virus
addition to target cells. A concentration of contrajervin pre-
viously shown in dose–response studies to be 100% protective
was utilized. Complete protection was conﬁrmed when the
compound was added immediately following virus addition.
Surprisingly, delayed addition of contrajervin, even up to
eleven hours after virus addition, resulted in nearly complete
protection of the cells. These data suggest that the compound
is acting by a second mechanism/target which contributes to its
cytoprotective activity.Microcolumns packed with chitin were loaded with contra-
jervin or WGA as a positive control, and eluted at neutral and
low pH. Reversed-phase HPLC of the resulting fractions
showed that contrajervin was present in the initial fraction that
was recycled through the column, while WGA was present
only in the fraction eluted with low pH buﬀer (data not
shown). These results indicated that contrajervin does not
exhibit strong binding aﬃnity toward chitin.
3.3. Sequence similarity
The Moraceae family is known to contain lectins, which
have anti-HIV activity of micromolar concentrations [7]. As
part of the original HTS screen to prioritize extracts, active
hits were tested to see if their activity was due to monosac-
charide-speciﬁc lectin-like properties. The original binding
assay was run with the extracts in the presence of mannose and
glcNAc (the only monosaccharides present on the recombinant
gp41 used in this assay), to see if the sugars decreased the
ability of the extracts to compete with CV-N binding to gp41.
Neither of the extracts displayed reduced binding to gp41 in
the presence of the sugars, therefore they did not appear to
contain monosaccharide-speciﬁc lectins (Fig. 2).
The monomers of treculavirin share a high sequence simi-
larity (68%) with contrajervin (Fig. 3). A search of the Gen-
Bank non-redundant database, BLASTP [12], for
identiﬁcation of protein sequence homology indicated strong
          1        46
CJN       ERDDHRCGPDYGNPSCSGDRCCSIYNWCGGGSSYCSGGSCRYQCWY
5        50
TVN      ERPDHQCGPDYGNPGCGAGRCCSIHGWCGSSADYCSGTSCQYQCSC
   23       67
chit      ERSDHRCGPNYGNPGCSEGRCCSVHGWCGGGANYCSGGNCDYQCW
Fig. 3. Aligned amino acid sequences of contrajervin (CJN) and tre-
culavirin (TVN) and the similar region of a deduced sequence of a class
I chitinase (CHI) from Ficus carica. Numbers to the top of the se-
quences indicate amino acid residue numbers. Sequence identities are
indicated by gray shading.
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72%) to a class I chitinase from Ficus carica (Moraceae) whose
sequence was deduced from isolated cDNA [13] (Fig. 3).
Contrajervin and treculavirin also showed homology (66% and
65%, respectively) to a hevein-like protein from Sambucus ni-
gra (Caprifoliaceae) [14] as well as a precursor of Urtica diocia
(Moraceae) agglutinin (UDA) isolectin (64% and 66%, re-
spectively) [15]. The amino acid sequences of both peptides are
cysteine/glycine rich which is characteristic of the chitin bind-
ing domain of chitin binding proteins. Because of the primary
sequence similarity of the peptides to chitin binding proteins,
we investigated the ability of contrajervin to bind to a chitin
substrate. Assay results indicated that although contrajervin
contains a primary structural motif similar to chitin-binding
proteins, it does not exhibit strong binding aﬃnity toward
chitin.
The gene encoding the class I chitinase from Ficus carica has
been characterized as a stress-related gene [13] and UDA has
been suggested to play a role in plant defense [16]. Although
the ecological function of the secondary metabolites from
Dorstenia and Treculia is unknown, they may also play a role
in plant defense.
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